Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Minoxidil
Drug ID BADD_D01473
Description A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Indications and Usage For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.
Marketing Status approved; investigational
ATC Code C02DC01; D11AX01
DrugBank ID DB00350
KEGG ID D00418
MeSH ID D008914
PubChem ID 4201
TTD Drug ID D0Y2CJ
NDC Product Code 73277-002; 82607-002; 83454-404; 0591-5642; 38779-0574; 11673-317; 30142-632; 0113-7798; 41163-798; 41250-749; 49035-905; 56062-798; 57483-540; 57483-542; 63940-385; 64942-2111; 68016-382; 69113-128; 71713-091; 71730-023; 72288-701; 72764-002; 72789-278; 79481-0070; 79903-072; 46204-0159; 54236-020; 11822-0114; 11822-0702; 30142-719; 51316-212; 53489-387; 57483-535; 63940-582; 63981-032; 69968-0031; 69968-0089; 71205-757; 71730-798; 72288-202; 72789-279; 72882-094; 81653-002; 82157-200; 82987-101; 83383-398; 0591-5643; 63934-007; 67438-020; 71052-063; 11509-0798; 11673-157; 11673-189; 11673-382; 11822-0606; 11822-0798; 0113-7202; 41250-202; 41250-428; 51326-160; 59450-211; 0363-0703; 68391-302; 69423-559; 69842-599; 70550-605; 72162-1490; 72484-096; 63629-1085; 65121-101; 68196-032; 71205-490; 71730-000; 72288-129; 72288-294; 72764-001; 81632-408; 82157-100; 82269-607; 40700-0008; 79572-022; 21130-273; 21130-750; 0113-1032; 49035-746; 49884-257; 50663-395; 53489-386; 56062-202; 56062-294; 63629-9299; 63629-9620; 64942-2110; 68084-204; 68391-294; 69113-129; 69423-586; 69842-598; 73277-001; 82429-200; 66219-0004; 67438-015; 11673-632; 11822-1033; 0113-0294; 0113-7129; 0113-7294; 37808-202; 41250-294; 51326-165; 56062-070; 0363-0032; 63629-1086; 0363-9090; 0363-9971; 63940-491; 63940-509; 63981-380; 63981-798; 65121-562; 68196-823; 69282-001; 69423-587; 81653-001; 81653-003; 81653-005; 17337-0027; 49452-4780; 51552-1334; 68981-036; 11673-707; 11822-0202; 11822-1323; 25280-006; 30142-294; 0113-7032; 37808-798; 43353-342; 51316-213; 63629-2230; 63629-2232; 0363-9091; 0363-9973; 63940-202; 69423-558; 69842-797; 70518-3419; 72484-095; 0009-5056; 62991-1105; 64162-0210; 11673-158; 11673-798; 11673-919; 0113-0798; 51326-161; 51672-2129; 55301-094; 56062-322; 59640-000; 59779-294; 0363-9972; 63940-032; 63981-294; 68788-8273; 69282-002; 71713-092; 71713-093; 71713-094; 72288-798; 81653-004; 51927-2885; 73005-0008; 80813-0022; 11673-431; 11822-0115; 41250-798; 42291-619; 49884-256; 51672-2128; 57483-530; 59726-115; 0363-2294; 0363-9970; 65121-102; 68196-469; 69968-0090; 71176-781; 71730-129; 71730-202; 71730-294; 82157-002; 82376-6006; 82376-6007; 0009-5230; 51552-0536; 11822-0129; 11822-1260; 25280-007; 0113-1129; 61269-094; 0363-1129; 0363-2798; 63629-2231; 63629-9433; 68016-006; 68084-205; 69968-0030; 71290-813; 80855-201; 81653-006; 82157-001; 82796-100; 10695-149; 76003-0748; 21130-163; 21130-819; 37808-833; 42291-618; 49035-294; 49539-001; 51326-166; 59450-210; 59726-116; 59779-202
UNII 5965120SH1
Synonyms Minoxidil | Rogaine | Regaine | U 10858 | Loniten
Chemical Information
Molecular Formula C9H15N5O
CAS Registry Number 38304-91-5
SMILES C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sexual dysfunction19.08.05.002; 21.03.02.003---
Sinus tachycardia02.03.03.0100.002806%
Skin disorder23.03.03.007---
Skin exfoliation23.03.07.003---
Skin hyperpigmentation23.05.01.0030.000701%
Skin irritation23.03.04.0090.001543%-
Skin striae23.01.05.0020.000701%-
Somnolence17.02.04.006; 19.02.05.0030.001052%
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Suicidal ideation19.12.01.003--
Swelling08.01.03.0150.001403%-
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.002455%
Tachycardia02.03.02.0070.013398%-
Therapeutic response decreased08.06.01.0160.001052%-
Therapeutic response unexpected08.06.01.0010.001543%-
Thrombocytopenia01.08.01.002---
Tinnitus04.04.01.002; 17.04.07.0040.000701%
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Virilism05.05.01.001; 21.10.04.001--
Vision blurred06.02.06.007; 17.17.01.0100.000701%
Visual impairment06.02.10.013---
Vomiting07.01.07.0030.007295%
Weight increased13.15.01.006--
Retinal toxicity06.09.03.013; 12.03.01.0360.001403%-
Peripheral swelling02.05.04.015; 08.01.03.053---
Application site inflammation08.02.01.024; 12.07.01.0240.003577%-
Lymphatic disorder01.09.01.003---
Alcohol withdrawal syndrome08.06.02.002; 19.07.06.0050.001052%-
Skin burning sensation17.02.06.009; 23.03.03.0210.003577%-
Blood alkaline phosphatase increased13.04.02.004--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages